Literature DB >> 19122569

Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair.

Jeffrey L Saver1.   

Abstract

Choline precursors promote repair and growth of cell membranes and hold promise in a variety of neurologic diseases, including ischemic and hemorrhagic stroke. Citicoline, the most well-studied choline agent precursor, is widely prescribed throughout the world and recently became available in the United States as a dietary supplement. In experimental stroke models, citicoline conferred acute neuroprotection and enhanced neuroplasticity and neurorepair in the subacute period. Although individual human stroke trials have been inconclusive, meta-analysis of 10 trials enrolling 2279 patients suggests patients receiving citicoline had substantially reduced frequencies of death and disability. Reinvestigation of citicoline with modern neuroimaging and clinical trial methods are underway and will provide more definitive information regarding the mechanistic and clinical effects of this promising neurotherapeutic agent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19122569

Source DB:  PubMed          Journal:  Rev Neurol Dis        ISSN: 1545-2913


  25 in total

Review 1.  Choline and betaine in health and disease.

Authors:  Per Magne Ueland
Journal:  J Inherit Metab Dis       Date:  2010-05-06       Impact factor: 4.982

2.  The CITIRIVAD Study: CITIcoline plus RIVAstigmine in Elderly Patients Affected with Dementia Study.

Authors:  Alberto Castagna; Antonino Maria Cotroneo; Giovanni Ruotolo; Pietro Gareri
Journal:  Clin Drug Investig       Date:  2016-12       Impact factor: 2.859

Review 3.  Mitochondrial function in hypoxic ischemic injury and influence of aging.

Authors:  P Benson Ham; Raghavan Raju
Journal:  Prog Neurobiol       Date:  2016-06-16       Impact factor: 11.685

Review 4.  Neuroplasticity in the context of motor rehabilitation after stroke.

Authors:  Michael A Dimyan; Leonardo G Cohen
Journal:  Nat Rev Neurol       Date:  2011-01-18       Impact factor: 42.937

5.  Citicoline retards myopia progression following form deprivation in guinea pigs.

Authors:  Junfeng Mao; Shuangzhen Liu; Chunyan Fu
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-14

6.  The citicoline brain injury treatment (COBRIT) trial: design and methods.

Authors:  Ross Zafonte; William T Friedewald; Shing M Lee; Bruce Levin; Ramon Diaz-Arrastia; Beth Ansel; Howard Eisenberg; Shelly D Timmons; Nancy Temkin; Thomas Novack; Joseph Ricker; Randall Merchant; Jack Jallo
Journal:  J Neurotrauma       Date:  2009-12       Impact factor: 5.269

7.  Citicoline induces angiogenesis improving survival of vascular/human brain microvessel endothelial cells through pathways involving ERK1/2 and insulin receptor substrate-1.

Authors:  Jerzy Krupinski; Manal Abudawood; Sabine Matou-Nasri; Raid Al-Baradie; Eugen Bogdan Petcu; Carlos Justicia; Anna Planas; Donghui Liu; Norma Rovira; Marta Grau-Slevin; Julio Secades; Mark Slevin
Journal:  Vasc Cell       Date:  2012-12-10

8.  Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study.

Authors:  Antonino Maria Cotroneo; Alberto Castagna; Salvatore Putignano; Roberto Lacava; Fausto Fantò; Francesco Monteleone; Filomena Rocca; Alba Malara; Pietro Gareri
Journal:  Clin Interv Aging       Date:  2013-02-05       Impact factor: 4.458

9.  The efficacy of citroline in the treatment of ischemic stroke and primary hypertensive intracereral hemorrhage; a review article.

Authors:  Seyed Ali Mousavi; Fariborz Khorvash; Tahereh Hoseini
Journal:  ARYA Atheroscler       Date:  2010

10.  Cytidine-5-diphosphocholine reduces microvascular permeability during experimental endotoxemia.

Authors:  Karsten Schmidt; Jochen Frederick Hernekamp; Miriam Doerr; Aleksandar R Zivkovic; Thorsten Brenner; Andreas Walther; Markus A Weigand; Stefan Hofer
Journal:  BMC Anesthesiol       Date:  2015-08-01       Impact factor: 2.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.